TY - JOUR T1 - ERGOT JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 203 LP - 230 VL - 1 IS - 2 AU - W. H. CRONYN AU - V. E. HENDERSON Y1 - 1909/08/01 UR - http://jpet.aspetjournals.org/content/1/2/203.abstract N2 - 1. That most galenical preparations of ergot contain considerable amounts of the active principles but do not show any great or marked action when given per os. Their usually recommended doses are much too small. 2. That ergotoxine is a highly active alkaloid and has the properties of ergot most desired in medicine. 3. That ergotoxine brings about a long enduring contraction of the walls of arterioles, and increases the movements of the uterus. 4. That this action is feeble when ergotoxine is given per os, but more marked in subcutaneous injections and much more marked when given intravenously. 5. That in cases where a rapid and certain action is wished either in shock or in post-partum hæmorrhage we would recommend intravenous administration. We would recommend further, if the effect proved too evanescent to achieve the results desired, that suprarenal be administered subsequently in repeated small doses. ER -